Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs

Current Opinion in Structural Biology

Volumn 27, Issue 1, 2014, Pages 102-112

  Jost, Christian ^a   Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANKYRIN; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BINDING PROTEIN; BISPECIFIC ANTIBODY; CARRIER PROTEINS AND BINDING PROTEINS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; FC RECEPTOR; FIBRONECTIN; FIBRONECTIN TYPE 3; IMMUNOGLOBULIN BINDING PROTEIN A; IMMUNOGLOBULIN G; LEUCINE RICH REPEAT PROTEIN; LYMPHOCYTE RECEPTOR; METAL; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PROTEIN A; PROTEIN DARP; PROTEIN HER3; PROTEIN TYROSINE KINASE; RIBONUCLEASE A; RIBONUCLEASE INHIBITOR; SCAFFOLD PROTEIN; TETRATRICOPEPTIDE REPEAT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; ACRIFLAVINE RESISTANCE PROTEIN; AMINOGLYCOSIDE PHOSPHOTRANSFERASE; ANTIBODY; CASPASE 2; CASPASE 3; CASPASE 7; CASPASE 8; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DARPIN; DIGOXIGENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FLUORESCEIN; HUMAN SMALL UBIQUITIN LIKE MODIFIER 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; MALTOSE BINDING PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; TUBULIN; UBIQUITIN; YEAST SMALL UBIQUITIN LIKE MODIFIER; HYBRID PROTEIN;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; BINDING AFFINITY; BINDING SITE; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR DOMAIN; FLUORESCENCE ACTIVATED CELL SORTING; GENE FUSION; GENE LIBRARY; HEAVY CHAIN; HUMAN; ISOTOPE LABELING; LIGHT CHAIN; METAL BINDING; MOLECULAR EVOLUTION; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RADIOIMMUNO DIAGNOSTICS; REVIEW; SERODIAGNOSIS; VARIABLE DOMAIN; ANTIBODY SPECIFICITY; COMPUTER AIDED DESIGN; PH MEASUREMENT; PROTEIN ANALYSIS; PROTEIN TARGETING; BIOLOGY; DIRECTED MOLECULAR EVOLUTION; GENETICS; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, BISPECIFIC; COMPUTATIONAL BIOLOGY; DIRECTED MOLECULAR EVOLUTION; HUMANS; IMMUNOGLOBULIN G; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS;

EID: 84904321648     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2014.05.011     Document Type: Review

References (65)

1. Gilbreth R.N., Koide S. Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr Opin Struct Biol 2012, 22:413-420.
2. Kuroda D., Shirai H., Jacobson M.P., Nakamura H. Computer-aided antibody design. Protein Eng Des Sel 2012, 25:507-521.
3. Binz H.K., Amstutz P., Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005, 23:1257-1268.
4. Koide A., Bailey C.W., Huang X., Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998, 284:1141-1151.
5. Bloom L., Calabro V. FN3: a new protein scaffold reaches the clinic. Drug Discov Today 2009, 14:949-955.
6. Wojcik J., Hantschel O., Grebien F., Kaupe I., Bennett K.L., Barkinge J., Jones R.B., Koide A., Superti-Furga G., Koide S. A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol 2010, 17:519-527.
7. Koide A., Wojcik J., Gilbreth R.N., Hoey R.J., Koide S. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol 2012, 415:393-405.
8. Eggenstein E., Eichinger A., Kim H.J., Skerra A. Structure-guided engineering of anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy. J Struct Biol 2013, 185:203-214.
9. Kim H.J., Eichinger A., Skerra A. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc 2009, 131:3565-3576.
10. DeNardo D.G., Xiong C.Y., Shi X.B., DeNardo G.L., DeNardo S.J. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001, 16:525-535.
11. Yazaki P.J., Lee B., Channappa D., Cheung C.W., Crow D., Chea J., Poku E., Li L., Andersen J.T., Sandlie I., et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 2013, 26:187-193.
12. Gebauer M., Schiefner A., Matschiner G., Skerra A. Combinatorial design of an anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin. J Mol Biol 2013, 425:780-802.
13. Waibel R., Alberto R., Willuda J., Finnern R., Schibli R., Stichelberger A., Egli A., Abram U., Mach J.P., Plückthun A., et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999, 17:897-901.
14. DeNardo S.J., DeNardo G.L., DeNardo D.G., Xiong C.Y., Shi X.B., Winthrop M.D., Kroger L.A., Carter P. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Cancer Res 1999, 5:3213s-3218s.
15. 18F labeling of the HER2-binding affibody molecule ZHER2:2891 including preclinical assessment. J Nucl Med 2013, 54:1981-1988.
16. ® molecule for in vivo molecular imaging. Br J Radiol 2014, 87:20130484.
17. Tolmachev V., Orlova A., Andersson K. Methods for radiolabelling of monoclonal antibodies. Methods Mol Biol 2014, 1060:309-330.
18. Zahnd C., Kawe M., Stumpp M.T., de Pasquale C., Tamaskovic R., Nagy-Davidescu G., Dreier B., Schibli R., Binz H.K., Waibel R., et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010, 70:1595-1605.
19. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
20. Main E.R., Jackson S.E., Regan L. The folding and design of repeat proteins: reaching a consensus. Curr Opin Struct Biol 2003, 13:482-489.
21. Main E.R., Lowe A.R., Mochrie S.G., Jackson S.E., Regan L. A recurring theme in protein engineering: the design, stability and folding of repeat proteins. Curr Opin Struct Biol 2005, 15:464-471.
22. Grove T.Z., Cortajarena A.L., Regan L. Ligand binding by repeat proteins: natural and designed. Curr Opin Struct Biol 2008, 18:507-515.
23. Tamaskovic R., Simon M., Stefan N., Schwill M., Plückthun A. Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol 2012, 503:101-134.
24. Stumpp M.T., Forrer P., Binz H.K., Plückthun A. Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J Mol Biol 2003, 332:471-487.
25. Kajava AV: Review: proteins with repeated sequence - structural prediction and modeling. J Struct Biol 2001, 134:132-144.
26. Binz H.K., Amstutz P., Kohl A., Stumpp M.T., Briand C., Forrer P., Grütter M.G., Plückthun A. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004, 22:575-582.
27. Pancer Z., Amemiya C.T., Ehrhardt G.R., Ceitlin J., Gartland G.L., Cooper M.D. Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey. Nature 2004, 430:174-180.
28. Alder M.N., Rogozin I.B., Iyer L.M., Glazko G.V., Cooper M.D., Pancer Z. Diversity and function of adaptive immune receptors in a jawless vertebrate. Science 2005, 310:1970-1973.
29. Saha N.R., Smith J., Amemiya C.T. Evolution of adaptive immune recognition in jawless vertebrates. Semin Immunol 2010, 22:25-33.
30. Lee S.C., Park K., Han J., Lee J.J., Kim H.J., Hong S., Heu W., Kim Y.J., Ha J.S., Lee S.G., et al. Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc Natl Acad Sci U S A 2012, 109:3299-3304.
31. Boersma Y.L., Plückthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 2011, 22:849-857.
32. Binz H.K., Plückthun A. Engineered proteins as specific binding reagents. Curr Opin Biotechnol 2005, 16:459-469.
33. Friedrich K., Hanauer J.R., Prüfer S., Münch R.C., Völker I., Filippis C., Jost C., Hanschmann K.M., Cattaneo R., Peng K.W., et al. DARPin-targeting of measles virus: unique bispecificity effective oncolysis, and enhanced safety. Mol Ther 2013, 21:849-859.
34. Mann A., Friedrich N., Krarup A., Weber J., Stiegeler E., Dreier B., Pugach P., Robbiani M., Riedel T., Moehle K., et al. Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. J Virol 2013, 87:5868-5881.
35. Schilling J., Schöppe J., Plückthun A. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J Mol Biol 2013, 426:691-721.
36. Collis A.V., Brouwer A.P., Martin A.C. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 2003, 325:337-354.
37. Nelson B., Sidhu S.S. Synthetic antibody libraries. Methods Mol Biol 2012, 899:27-41.
38. Rajan S., Sidhu S.S. Simplified synthetic antibody libraries. Methods Enzymol 2012, 502:3-23.
39. Kummer L., Hsu C.W., Dagliyan O., MacNevin C., Kaufholz M., Zimmermann B., Dokholyan N.V., Hahn K.M., Plückthun A. Knowledge-based design of a biosensor to quantify localized ERK activation in living cells. Chem Biol 2013, 20:847-856.
40. Kummer L., Parizek P., Rube P., Millgramm B., Prinz A., Mittl P.R., Kaufholz M., Zimmermann B., Herberg F.W., Plückthun A. Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries. Proc Natl Acad Sci U S A 2012, 109:E2248-E2257.
41. Gulyani A., Vitriol E., Allen R., Wu J., Gremyachinskiy D., Lewis S., Dewar B., Graves L.M., Kay B.K., Kuhlman B., et al. A biosensor generated via high-throughput screening quantifies cell edge Src dynamics. Nat Chem Biol 2011, 7:437-444.
42. Martin-Killias P., Stefan N., Rothschild S., Plückthun A., Zangemeister-Wittke U. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 2011, 17:100-110.
43. Jost C., Schilling J., Tamaskovic R., Schwill M., Honegger A., Plückthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 2013, 21:1979-1991.
44. Grebien F., Hantschel O., Wojcik J., Kaupe I., Kovacic B., Wyrzucki A.M., Gish G.D., Cerny-Reiterer S., Koide A., Beug H., et al. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 2011, 147:306-319.
45. Dreier B., Honegger A., Hess C., Nagy-Davidescu G., Mittl P.R., Grütter M.G., Belousova N., Mikheeva G., Krasnykh V., Plückthun A. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A 2013, 110:E869-E877.
46. Kirby I., Davison E., Beavil A.J., Soh C.P., Wickham T.J., Roelvink P.W., Kovesdi I., Sutton B.J., Santis G. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol 1999, 73:9508-9514.
47. Klein C., Sustmann C., Thomas M., Stubenrauch K., Croasdale R., Schanzer J., Brinkmann U., Kettenberger H., Regula J.T., Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012, 4:653-663.
48. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012, 12:12.
49. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010, 10:301-316.
50. Ridgway J.B., Presta L.G., Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996, 9:617-621.
51. Atwell S., Ridgway J.B., Wells J.A., Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997, 270:26-35.
52. Merchant A.M., Zhu Z., Yuan J.Q., Goddard A., Adams C.W., Presta L.G., Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998, 16:677-681.
53. Schaefer W., Regula J.T., Bahner M., Schanzer J., Croasdale R., Durr H., Gassner C., Georges G., Kettenberger H., Imhof-Jung S., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011, 108:11187-11192.
54. Fenn S., Schiller C.B., Griese J.J., Duerr H., Imhof-Jung S., Gassner C., Moelleken J., Regula J.T., Schaefer W., Thomas M., et al. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PLoS ONE 2013, 8:e61953.
55. Lewis S.M., Wu X., Pustilnik A., Sereno A., Huang F., Rick H.L., Guntas G., Leaver-Fay A., Smith E.M., Ho C., et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014, 32:191-198.
56. Leaver-Fay A., Jacak R., Stranges P.B., Kuhlman B. A generic program for multistate protein design. PLoS ONE 2011, 6:e20937.
57. Röthlisberger D., Honegger A., Plückthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005, 347:773-789.
58. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., et al. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
59. Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C.V., Stawicki S., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
60. Wozniak-Knopp G., Bartl S., Bauer A., Mostageer M., Woisetschlager M., Antes B., Ettl K., Kainer M., Weberhofer G., Wiederkum S., et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010, 23:289-297.
61. Strauch E.M., Fleishman S.J., Baker D. Computational design of a pH-sensitive IgG binding protein. Proc Natl Acad Sci U S A 2013, 111:675-680.
62. Fleishman S.J., Whitehead T.A., Ekiert D.C., Dreyfus C., Corn J.E., Strauch E.M., Wilson I.A., Baker D. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 2011, 332:816-821.
63. Du X., Wang W., Kim R., Yakota H., Nguyen H., Kim S.H. Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 2001, 40:14166-14172.
64. Whitehead T.A., Chevalier A., Song Y., Dreyfus C., Fleishman S.J., De Mattos C., Myers C.A., Kamisetty H., Blair P., Wilson I.A., et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol 2012, 30:543-548.
65. Fanning S.W., Murtaugh M.L., Horn J.R. A combinatorial approach to engineering a dual-specific metal switch antibody. Biochemistry 2011, 50:5093-5095.